Jeffrey Nascimento, DO
Pulmonary Disease · Hartford, CTNPI 1235256934
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $191,096 of the $212,830 with a category attached, or 89.8%. GSK accounts for 85.3% of it on its own, with 36 other manufacturers making up the rest. Reporting peaked in 2023 at $79,827 and has fallen 90.5% since, to $7,605 in 2025. Among pulmonary disease clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 886 payments — averaging $240.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$182K
- Boehringer Ingelheim$17K
- Axsome Therapeutics, Inc.$5K
- AstraZeneca$3K
- Harmony Biosciences LLC$888
- Jazz Pharmaceuticals Inc.$690
- plus $4K from 31 others
What the payments were for
- Speaking & faculty fees$191,09690%
- Travel & lodging$2,3511%
- Food & beverage$19,2329%
- Education$1520%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 403 | $181,542 |
| Boehringer Ingelheim | 44 | $16,964 |
| Axsome Therapeutics, Inc. | 7 | $4,965 |
| AstraZeneca(2 entities) | 143 | $3,466 |
| Harmony Biosciences LLC | 34 | $888 |
| Jazz Pharmaceuticals Inc. | 32 | $690 |
| Mylan Specialty L.p. | 27 | $564 |
| Amgen | 14 | $412 |
| Regeneron Healthcare Solutions, Inc. | 19 | $410 |
| Electromed, Inc. | 30 | $313 |
| Verona Pharma, Inc. | 12 | $305 |
| Genentech USA, Inc. | 8 | $255 |
| Sunovion Pharmaceuticals Inc. | 22 | $244 |
| Avadel CNS Pharmaceuticals, LLC | 9 | $227 |
| Johnson & Johnson | 15 | $219 |
| Insmed, Inc. | 9 | $164 |
| Actelion Pharmaceuticals US, Inc. | 6 | $145 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $134 |
| E.r. Squibb & Sons, L.L.C. | 7 | $125 |
| Pfizer | 6 | $116 |
| Novartis | 4 | $86 |
| Merck | 4 | $80 |
| ZOLL Respicardia, Inc. | 2 | $66 |
| Circassia Inc. | 4 | $58 |
| Sanofi | 2 | $54 |
| Arbor Pharmaceuticals, Inc. | 2 | $43 |
| 3b Medical, Inc. | 2 | $37 |
| Grifols USA, LLC | 2 | $36 |
| Mallinckrodt Hospital Products Inc. | 2 | $34 |
| Viatris Specialty LLC | 1 | $34 |
| Philips North America LLC | 2 | $30 |
| AbbVie | 1 | $24 |
| Boston Scientific | 1 | $23 |
| Lilly USA, LLC | 1 | $22 |
| Advanced Respiratory, Inc | 1 | $21 |
| Mallinckrodt Enterprises LLC | 1 | $16 |
| Eisai Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$212,830 in reported general payments places this provider in the 95th percentile of 255 pulmonary disease providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 162 | $135,292 |
| TezspireTezepelumab-Ekko | 21 | $93,331 |
| Breo ElliptaFluticasone/Vilanterol | 53 | $26,818 |
| Spiriva RespimatTiotropium Bromide | 28 | $21,601 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 20 | $16,147 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 24 | $15,382 |
| Modafinil | 23 | $5,642 |
| BelsomraSuvorexant | 13 | $5,563 |
| DayvigoLemborexant | 16 | $5,442 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 13 | $2,430 |
| Armodafinil | 36 | $2,093 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 94 | $1,899 |
| Doxepin Hcl | 14 | $1,698 |
| Ventolin HfaAlbuterol Sulfate | 14 | $753 |
| Trazodone Hcl | 25 | $386 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $181,542 | $178,257235 claims |
| AstraZenecaTezspire, Breztri Aerosphere | $3,466 | $108,71345 claims |
| Boehringer IngelheimSpiriva Respimat | $16,964 | $21,60128 claims |
| MerckBelsomra | $80 | $5,56313 claims |
| Eisai Inc.Dayvigo | $16 | $5,44216 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 255 pulmonary disease providers in Connecticut.
Other pulmonary disease in Hartford
- Raj ParikhHartford$386K
- Patrick TroyHartford$385K
- Daniel GerardiHartford$156K
- James PopeHartford$125K
- Anil MaggeHartford$74K
- Francoise RouxHartford$39K
- Eric ShoreHartford$35K
- John RussomannoHartford$18K
- Meredith HolubHartford$14K
- Jordan PownerHartford$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.